Mix-and-match vax effective against COVID: Lancet

People who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine followed by an mRNA vaccine shot had a lower risk of infection compared to those immunised with both doses of the AstraZeneca preventive, according to a nationwide study in Sweden.

Since the use of AstraZeneca’s vector-based vaccine against COVID-19 was halted for people younger than 65 years of age due to safety concerns, all individuals in Sweden who had already received their first dose of this vaccine were recommended an mRNA vaccine as their second dose.

Having received any of the approved vaccines is better compared to no vaccine, and two doses are better than one, said Peter Nordstrom, a professor at Umea University, Sweden.

However, our study shows a greater risk reduction for people who received an mRNA vaccine after having received a first dose of a vector-based, as compared to people having received the vector-based vaccine for both doses, Nordstrom said. The study, published in The Lancet Regional Health – Europe journal on Monday, is based on nationwide registry data from the Public Health Agency of Sweden, the National Board of Health and Welfare, and Statistics Sweden.

0

0